

**AMENDMENTS TO THE CLAIMS**

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-13. (Canceled)

14. (Currently amended) A method for treating a mood disorder in a human patient, which comprises administering to a patient in need thereof a therapeutically effective amount of ~~one or more of the cannabinoids~~ cannabichromene (CBC) ~~and/or cannabichromene propyl analogue (CBC-V)~~

wherein the CBC ~~and/or CBC-V~~ is substantially pure or is an extract from a cannabis plant that contains greater than or equal to 30% CBC ~~and/or CBC-V~~ of the total cannabinoid content, and

wherein the mood disorder is morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.

15.-17. (Canceled)

18. (Currently amended) The method according to claim 14 wherein the ~~one or more cannabinoids~~ CBC is present in an extract of at least one cannabis plant.

19. (Currently amended) The method according to claim 14, wherein the ~~compound or the composition~~ CBC is administered nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by installation directly into the bladder.

20.-24. (Canceled)

25. (Previously presented) The method according to claim 18, wherein the extract comprises substantially all the naturally occurring cannabinoids in said at least one cannabis plant.

26. (Currently amended) The method according to claim 18, wherein the extract is enriched for CBC and/or ~~CBC-V~~.
27. (Currently amended) The method according to claim 14, wherein the CBC compound is administered in an isolated and substantially pure form.
28. (Currently amended) The method according to claim 14, wherein the CBC compound is administered together with one or more pharmaceutically acceptable diluents, excipients or carriers.